DUBLIN, June 15, 2022 /PRNewswire/ — The “Market Overview of Invasive Brain-Computer interface (BCI)” report has been added to ResearchAndMarkets.com’s offering.
Patients with Locked-in Syndrome, who are unable to communicate, represent the target population of Brain-computer Interface research over the past 20 years. In this context, real-time decoding of macroscopic brain states becomes critical.
Patients with Locked-In Syndrome often experience opsoclonus-myoclonus, a condition in which the eyes seemingly randomly and involuntarily move rapidly in the horizontal, vertical, and diagonal directions.
This makes communications extremely difficult, if not impossible, for patients relying on eye communication and typical assistive technology such as the detection of eye movement and voice prosthetics are ineffective, and in the vast majority useless.
Key Topics Covered:
Overview
Number of Motor paralysis due to Spinal Cord Injury
Number of scholarly citations since 2000 on the subject of Locked-in Syndrome
Invasive BCI Companies Funding, million USD
Brain-Computer Interface (BCI)
Risks of using Invasive Brain-Computer Interface (iBCI)
Companies specialized in ECoG microelectrodes with disclosed funding
Companies specialized in Utah microelectrodes with disclosed funding
Takeaways
Companies Mentioned
For more information about this report visit https://www.researchandmarkets.com/r/afe2y0
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://healthtechnologynet.com/wp-content/uploads/2022/06/Research_and_Markets_Logo-5.jpg
View original content:https://www.prnewswire.com/news-releases/world-invasive-brain-computer-interface-bci-market-overview-2022-stimulation-recording-utah-electrodes-microecog-ecog-electrodes-301568520.html
SOURCE Research and Markets
* Efficacy, safety, and cost-effectiveness of Thermobalancing therapy and Dr Allen's Devices were showcased at…
FINANCIERE DE TUBIZE SA/NV Allée de la Recherche 60, 1070 Brussels Contact: investorrelations@financiere-tubize.be Annual Report…
PLEASANTON, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP…
Ibogaine By David Dardashti Revolutionizes Solar Energy Efficiency Through Radiation Generators Einstein A young and…
NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM)…
TORONTO and HAIFA, Israel, March 15, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX)…